Biofrontera

Biofrontera Capital Intensity

The Capital Intensity Ratio of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 156.52 %. In the previous year, Capital Intensity Ratio was 247.49 % — a change of -36.76% (lower).

Capital Intensity

156.52 %

YoY

-36.76%

Last updated:

Capital Intensity Ratio of Biofrontera is 2025 156.52 % . Capital Intensity Ratio of Biofrontera was 2024 247.49 % . It decreases by -36.76% lower compared to the previous year.

The Biofrontera Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
185.40 EUR
Jan 1, 2019
186.67 EUR
Jan 1, 2020
185.83 EUR
Jan 1, 2021
264.45 EUR
Jan 1, 2022
127.15 EUR
Jan 1, 2023
95.30 EUR
Jan 1, 2024
247.49 EUR
Jan 1, 2025
156.52 EUR
The Biofrontera Capital Intensity history
YEARCapital IntensityYoY
156.52 %-36.76%
247.49 %+159.71%
95.30 %-25.05%
127.15 %-51.92%
264.45 %+42.31%
185.83 %-0.45%
186.67 %+0.68%
185.40 %+12.33%
165.06 %-57.63%
389.52 %+69.70%
229.53 %-49.29%
452.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Capital Intensity Ratio of Biofrontera is 156.52 % in 2025.

Capital Intensity Ratio of Biofrontera changed from 247.49 % to 156.52 %, representing a -36.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biofrontera

All Key Metrics — Biofrontera